Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
Conditions
Interventions
Renal Autologous Cell Therapy (REACT)
Locations
5
United States
Kidney Associates of Colorado, P.C. - Frenova
Denver, Colorado, United States
Nephrology Associates
Newark, Delaware, United States
Boise Kidney and Hypertension Institute - Frenova
Nampa, Idaho, United States
Paragon Health, PC d/b/a Nephrology Center, PC - Frenova
Kalamazoo, Michigan, United States
Nephrology and Hypertension Associates Ltd - Frenova
Tupelo, Mississippi, United States
Start Date
July 27, 2021
Primary Completion Date
May 20, 2025
Completion Date
May 20, 2025
Last Updated
March 13, 2026
NCT07224321
NCT06278207
NCT07051005
NCT05728216
NCT06887049
NCT04592640
Lead Sponsor
Prokidney
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions